Company Will Also Provide Update on Clinical Programs
SAN DIEGO, Jan. 30 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that the Company will report fourth quarter and
year-end 2003 financial results after the Nasdaq market closes Thursday,
January 29, 2004. Neurocrine will also host a live conference call and
Webcast to discuss its year-end financial results and provide a Company update
Friday morning, January 30, 2004 at 11:00 AM Eastern Standard Time (EST)/8:00
AM Pacific Standard Time (PST). Participants may access the live Conference
Call by dialing 1-800-245-3043 (U.S.) or 1-785-832-0326 (International). The
call can also be accessed via the Webcast through the Company's website at
http://www.neurocrine.com or alternatively through a link provided by
PR Newswire at http://www.firstcallevents.com/service/ajwz397957067gf12.html .
Gary A. Lyons, President and Chief Executive Officer and Paul W. Hawran,
Executive Vice President and Chief Financial Officer of Neurocrine Biosciences
will present the Company's 2003 year-end financial results and provide an
update on the Company's clinical programs. If you are unable to attend the
Webcast and would like further information on this announcement please contact
Claudia Jones or Elizabeth Foster in the Investor Relations Department at
Neurocrine Biosciences at (858) 658-7600. A replay of the Conference Call
will be available by dialing 1-800-753-5207 (US) or 1-402-220-2156
(International) and will be archived until Friday, February 13, 2004.
Neurocrine Biosciences, Inc. is a product-based biopharmaceutical company
focused on neurological and endocrine diseases and disorders. Our product
candidates address some of the largest pharmaceutical markets in the world
including insomnia, anxiety, depression, malignant brain tumors and peripheral
cancers, diabetes, multiple sclerosis, irritable bowel syndrome, eating
disorders, pain, stroke, and certain female health disorders. Neurocrine
Biosciences, Inc. news releases are available through the Company's website
via the Internet at http://www.neurocrine.com .
SOURCE Neurocrine Biosciences, Inc.